Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Medicine and Surgery
Medical Oncologist, Breast Cancer Coordinator
Medical Oncology Dpt, Hospital 12 de Octubre and HM Hospitales
Professor of Medicine
University of Leuven
Head, Digestive Oncology Unit
University Hospital Gasthuisberg
Associate Professor, Thoracic Oncology
Director, Thoracic Oncology Program
Department of Medical Oncology
New York University
New York, New York
Senior Clinical Editor
Associate Scientific Director
Senior Scientific Director
Associate Director, Scientific Services
Senior Director, Educational Strategy
Senior Director, Oncology Programs and Partnership Development
Director, CME Program Development
Associate Director, Educational Strategy
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is intended for global physicians and other healthcare professionals who care for patients with cancer.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 15, 2021, through December 14, 2022:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Clinical Care Options (CCO) commentary: Joel Neal, MD, discusses management of non-small-cell lung cancer (NSCLC) with uncommon EGFR mutations
Dr Yara Abdou discusses BRCA mutation testing and adjuvant therapy with olaparib in BRCA-mutated, HER2-negative early breast cancer, from Clinical Care Options (CCO)
Slideset from Dr Yara Abdou on adjuvant olaparib in BRCA1/2-mutated, HER2-negative early breast cancer, from Clinical Care Options (CCO)
Module from Clinical Care Options (CCO): Christine Chio, PharmD, BCOP; Lipika Goyal, MD; and Caroline Kuhlman, NP, discuss current treatment of cholangiocarcinoma, including the use of biomarkers